The Strange Case of Martin Shkreli Is Wrapping Up

In February 2013, Martin Shkreli was contemplating a deal that involved acquiring shares of Retrophin, the pharmaceutical company he ran, at below the market price. Mr. Shkreli crudely dismissed the advice.

from Pocket http://ift.tt/2w0xMJI
via IFTTT

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s